Clinical Trials

There is a clinical trial investigating the use of a recommended Phase 2 dose of a dual PI3 kinase/ HDAC inhibitor drug, CUDC-907, that has been shown to have potent activity against cultured NMC cells.
Information about this trial can be found at the following link:

https://clinicaltrials.gov/ct2/show/NCT02307240?term=cudc-907&rank=2

For inquiries regarding entry into these trials, please contact Dr. Chris French at cfrench@partners.org , tel 617 525-4415.

Copyright © 2011 International NUT Midline Carcinoma Registry. All Rights Reserved.